<DOC>
	<DOC>NCT02250508</DOC>
	<brief_summary>The main objectives of the study were - to compare the pharmacokinetics (PK) of Optivate速 and Haemate P速 in various types of vonWillebrand disease (VWD) using the results from the VWF: RCo, VWF:Ag, VWF:CBA and Factor VIII assays. - to compare the clinical tolerance and safety of these two treatments after single IV infusions in subjects with VWD.</brief_summary>
	<brief_title>A Study to Compare the Pharmacokinetics and Safety of Optivate速 and Haemate P速 in Patients With Von Willebrand Disease.</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Previously treated subjects of at least 12 years of age, with any type of VWD were eligible for entry into this study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>